amass_scan_tripleharm_by.txt
· 3.3 KiB · Text
Sin formato
triplepharm.by (FQDN) --> mx_record --> mail.triplepharm.by (FQDN)
mail.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress)
93.84.0.0/15 (Netblock) --> contains --> 93.84.97.177 (IPAddress)
6697 (ASN) --> managed_by --> BELPAK-AS BELPAK, BY (RIROrganization)
6697 (ASN) --> announces --> 93.84.0.0/15 (Netblock)
triplepharm.by (FQDN) --> ns_record --> ns2.hoster.by (FQDN)
triplepharm.by (FQDN) --> ns_record --> ns1.hoster.by (FQDN)
triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
autodiscover.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress)
www.en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
www.en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:7::84:12e (IPAddress)
93.125.99.0/24 (Netblock) --> contains --> 93.125.99.66 (IPAddress)
6697 (ASN) --> announces --> 2a0a:7d80::/47 (Netblock)
6697 (ASN) --> announces --> 93.125.99.0/24 (Netblock)
ftp.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
ftp.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
localhost.triplepharm.by (FQDN) --> a_record --> 127.0.0.1 (IPAddress)
localhost.triplepharm.by (FQDN) --> aaaa_record --> ::1 (IPAddress)
127.0.0.0/8 (Netblock) --> contains --> 127.0.0.1 (IPAddress)
::/127 (Netblock) --> contains --> ::1 (IPAddress)
0 (ASN) --> managed_by --> Not routed (RIROrganization)
0 (ASN) --> managed_by --> Reserved Network Address Blocks (RIROrganization)
0 (ASN) --> announces --> 127.0.0.0/8 (Netblock)
0 (ASN) --> announces --> ::/127 (Netblock)
en.triplepharm.by (FQDN) --> mx_record --> mailbe05.hoster.by (FQDN)
ns1.hoster.by (FQDN) --> a_record --> 93.125.30.200 (IPAddress)
ns1.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1::6:0 (IPAddress)
en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress)
en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
93.125.30.0/23 (Netblock) --> contains --> 93.125.30.200 (IPAddress)
2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1::6:0 (IPAddress)
6697 (ASN) --> announces --> 93.125.30.0/23 (Netblock)
ns2.hoster.by (FQDN) --> a_record --> 185.179.82.104 (IPAddress)
ns2.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:3:1::8 (IPAddress)
_autodiscover._tcp.triplepharm.by (FQDN) --> srv_record --> mail.triplepharm.by (FQDN)
185.179.82.0/23 (Netblock) --> contains --> 185.179.82.104 (IPAddress)
2a0a:7d80:3::/48 (Netblock) --> contains --> 2a0a:7d80:3:1::8 (IPAddress)
12406 (ASN) --> managed_by --> BN-AS Belarussian data communication service provider. (RIROrganization)
12406 (ASN) --> announces --> 185.179.82.0/23 (Netblock)
35594 (ASN) --> managed_by --> TUTBY-AS (RIROrganization)
35594 (ASN) --> announces --> 2a0a:7d80:3::/48 (Netblock)
177.97.84.93.in-addr.arpa (FQDN) --> ptr_record --> mail.triplepharm.by (FQDN)
mailbe05.hoster.by (FQDN) --> a_record --> 93.125.31.215 (IPAddress)
mailbe05.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress)
93.125.30.0/23 (Netblock) --> contains --> 93.125.31.215 (IPAddress)
2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress)
ipv6.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress)
| 1 | triplepharm.by (FQDN) --> mx_record --> mail.triplepharm.by (FQDN) |
| 2 | mail.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress) |
| 3 | 93.84.0.0/15 (Netblock) --> contains --> 93.84.97.177 (IPAddress) |
| 4 | 6697 (ASN) --> managed_by --> BELPAK-AS BELPAK, BY (RIROrganization) |
| 5 | 6697 (ASN) --> announces --> 93.84.0.0/15 (Netblock) |
| 6 | triplepharm.by (FQDN) --> ns_record --> ns2.hoster.by (FQDN) |
| 7 | triplepharm.by (FQDN) --> ns_record --> ns1.hoster.by (FQDN) |
| 8 | triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress) |
| 9 | triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress) |
| 10 | autodiscover.triplepharm.by (FQDN) --> a_record --> 93.84.97.177 (IPAddress) |
| 11 | www.en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress) |
| 12 | www.en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress) |
| 13 | 2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:7::84:12e (IPAddress) |
| 14 | 93.125.99.0/24 (Netblock) --> contains --> 93.125.99.66 (IPAddress) |
| 15 | 6697 (ASN) --> announces --> 2a0a:7d80::/47 (Netblock) |
| 16 | 6697 (ASN) --> announces --> 93.125.99.0/24 (Netblock) |
| 17 | ftp.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress) |
| 18 | ftp.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress) |
| 19 | localhost.triplepharm.by (FQDN) --> a_record --> 127.0.0.1 (IPAddress) |
| 20 | localhost.triplepharm.by (FQDN) --> aaaa_record --> ::1 (IPAddress) |
| 21 | 127.0.0.0/8 (Netblock) --> contains --> 127.0.0.1 (IPAddress) |
| 22 | ::/127 (Netblock) --> contains --> ::1 (IPAddress) |
| 23 | 0 (ASN) --> managed_by --> Not routed (RIROrganization) |
| 24 | 0 (ASN) --> managed_by --> Reserved Network Address Blocks (RIROrganization) |
| 25 | 0 (ASN) --> announces --> 127.0.0.0/8 (Netblock) |
| 26 | 0 (ASN) --> announces --> ::/127 (Netblock) |
| 27 | en.triplepharm.by (FQDN) --> mx_record --> mailbe05.hoster.by (FQDN) |
| 28 | ns1.hoster.by (FQDN) --> a_record --> 93.125.30.200 (IPAddress) |
| 29 | ns1.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1::6:0 (IPAddress) |
| 30 | en.triplepharm.by (FQDN) --> a_record --> 93.125.99.66 (IPAddress) |
| 31 | en.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress) |
| 32 | 93.125.30.0/23 (Netblock) --> contains --> 93.125.30.200 (IPAddress) |
| 33 | 2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1::6:0 (IPAddress) |
| 34 | 6697 (ASN) --> announces --> 93.125.30.0/23 (Netblock) |
| 35 | ns2.hoster.by (FQDN) --> a_record --> 185.179.82.104 (IPAddress) |
| 36 | ns2.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:3:1::8 (IPAddress) |
| 37 | _autodiscover._tcp.triplepharm.by (FQDN) --> srv_record --> mail.triplepharm.by (FQDN) |
| 38 | 185.179.82.0/23 (Netblock) --> contains --> 185.179.82.104 (IPAddress) |
| 39 | 2a0a:7d80:3::/48 (Netblock) --> contains --> 2a0a:7d80:3:1::8 (IPAddress) |
| 40 | 12406 (ASN) --> managed_by --> BN-AS Belarussian data communication service provider. (RIROrganization) |
| 41 | 12406 (ASN) --> announces --> 185.179.82.0/23 (Netblock) |
| 42 | 35594 (ASN) --> managed_by --> TUTBY-AS (RIROrganization) |
| 43 | 35594 (ASN) --> announces --> 2a0a:7d80:3::/48 (Netblock) |
| 44 | 177.97.84.93.in-addr.arpa (FQDN) --> ptr_record --> mail.triplepharm.by (FQDN) |
| 45 | mailbe05.hoster.by (FQDN) --> a_record --> 93.125.31.215 (IPAddress) |
| 46 | mailbe05.hoster.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress) |
| 47 | 93.125.30.0/23 (Netblock) --> contains --> 93.125.31.215 (IPAddress) |
| 48 | 2a0a:7d80::/47 (Netblock) --> contains --> 2a0a:7d80:1:1:0:2:5:0 (IPAddress) |
| 49 | ipv6.triplepharm.by (FQDN) --> aaaa_record --> 2a0a:7d80:1:7::84:12e (IPAddress) |
links_tripleharm_by_WACDX.txt
· 19 KiB · Text
Sin formato
https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf
https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf
https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf
https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf
https://triplepharm.by/assets/files/0305instr/dorenem.pdf
https://triplepharm.by/assets/files/0305instr/dorenem.pdf
https://triplepharm.by/assets/files/0305instr/dorenem.pdf
https://triplepharm.by/assets/files/0305instr/imicinem.pdf
https://triplepharm.by/assets/files/0305instr/imicinem.pdf
https://triplepharm.by/assets/files/0305instr/imicinem.pdf
https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf
https://triplepharm.by/assets/files/0305instr/meropenem.pdf
https://triplepharm.by/assets/files/0305instr/meropenem.pdf
https://triplepharm.by/assets/files/0305instr/meropenem.pdf
https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF
https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf
https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
https://triplepharm.by/assets/files/0305instr/vankomicin.pdf
http://triplepharm.by:80/assets/files/1.pdf
http://triplepharm.by:80/assets/files/1.pdf
http://triplepharm.by:80/assets/files/1.pdf
http://triplepharm.by:80/assets/files/1.pdf
http://www.triplepharm.by:80/assets/files/1.pdf
http://triplepharm.by/assets/files/1.pdf
http://triplepharm.by/assets/files/1.pdf
http://triplepharm.by/assets/files/1.pdf
https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf
https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf
https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf
https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf
http://triplepharm.by:80/assets/files/annot-bronhomoss-utverzh_eng.pdf
http://triplepharm.by:80/assets/files/annot-fitokordium-utverzh_eng.pdf
http://triplepharm.by:80/assets/files/annot-gastroforte-utverzh_eng.pdf
http://triplepharm.by:80/assets/files/annot-sedakalm-utverzh_eng.pdf
http://triplepharm.by:80/assets/files/annot-sinu-fito-utverzh_eng.pdf
http://triplepharm.by:80/assets/files/annot-sinu-kapli-utverzh_eng.pdf
http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf
http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf
http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
https://triplepharm.by/assets/files/antibiotikorezistentnost.pdf
http://www.triplepharm.by:80/assets/files/Brinamid_eng.pdf
http://triplepharm.by:80/assets/files/bronhomoss-annot.pdf
http://triplepharm.by:80/assets/files/fitokordium-annot.pdf
http://triplepharm.by:80/assets/files/gastroforte-annot.pdf
http://triplepharm.by:80/assets/files/gastroforte-annot.pdf
http://triplepharm.by/assets/files/IMP-Kolistat-avg2016.PDF
http://www.triplepharm.by/assets/files/insruktiya-new-rus/Dorenem-instr.PDF
http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Klaribakcin.pdf
http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Kolistat-avg2016.PDF
http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefepim.PDF
http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefosulbaktam.PDF
http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-imicinem.PDF
http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF
http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna.PDF
http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF
http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-Tejkoplanin-2017.PDF
http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-triksocef(14.07.2017).pdf
http://www.triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Vankomicin.pdf
https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf
https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf
http://www.triplepharm.by/assets/files/insruktiya-new-rus/Meropenem-instr.PDF
http://triplepharm.by/assets/files/instr-kolistat-eng(1).pdf
http://triplepharm.by:80/assets/files/instr-kolistat-eng.pdf
http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf
http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf
http://triplepharm.by/assets/files/Instruction_Benustin_eng.pdf
http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf
http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf
http://triplepharm.by/assets/files/Instrukciya-Benustin.PDF
http://www.triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF
http://triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF
http://triplepharm.by:80/assets/files/instrukciya-cefepim-2015.pdf
http://triplepharm.by:80/assets/files/instrukciya-cefepim.PDF
http://triplepharm.by:80/assets/files/instrukciya-cefosulbaktam.pdf
http://triplepharm.by:80/assets/files/instrukciya-dorenem(1).pdf
http://triplepharm.by:80/assets/files/instrukciya-dorenem_eng.pdf
http://triplepharm.by:80/assets/files/instrukciya-imicinem.PDF
http://triplepharm.by:80/assets/files/instrukciya-imipenem-2015.pdf
http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf
http://triplepharm.by:80/assets/files/instrukciya-kapreocin(1).PDF
https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF
http://triplepharm.by:80/assets/files/instrukciya-kapreocin-angl.pdf
https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
http://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf
http://www.triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf
http://triplepharm.by:80/assets/files/instrukciya-kolistat(1).PDF
http://triplepharm.by:80/assets/files/instrukciya-Meropenem(1).pdf
http://triplepharm.by:80/assets/files/instrukciya-Triksocef_eng.pdf
http://triplepharm.by:80/assets/files/instrukciya-vankomicin(1).pdf
http://triplepharm.by:80/assets/files/instrukciya-vankomicin_eng.pdf
http://triplepharm.by:80/assets/files/InstrukciyaCefosulb-na-utv-----(1).pdf
http://triplepharm.by:80/assets/files/InstrukciyaMeropenem.pdf
http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf
http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf
http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf
http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf
http://triplepharm.by:80/assets/files/lechenie-sinegnojnoj-infekcii.pdf
https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf
https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf
https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf
https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf
https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf
http://triplepharm.by/assets/files/Saj-InstrukciyaPaulina_eng.pdf
http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf
http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
http://www.triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf
http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf
http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
http://www.triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf
http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf
http://triplepharm.by:80/assets/files/sedakalm-annot.pdf
http://triplepharm.by:80/assets/files/sinu-fito-annot.pdf
http://triplepharm.by:80/assets/files/sinu-kapli-annot.pdf
http://www.triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf
http://triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf
http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf
https://triplepharm.by/assets/files/tejkoplanin--tf-3.pdf
https://triplepharm.by/att1.pdf
https://triplepharm.by/att1.pdf
https://triplepharm.by/att1.pdf
https://triplepharm.by/licenziya.pdf
https://triplepharm.by/licenziya.pdf
https://triplepharm.by/licenziya.pdf
https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf
https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf
https://triplepharm.by/pdf/%D0%9F%D0%BE%D0%BB%D1%83%D0%B0%D0%B2%D1%82%D0%BE%D0%BC%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F%20%D0%BE%D0%B1%D0%BA%D0%B0%D1%82%D0%BA%D0%B0.pdf
https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf
https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf
https://triplepharm.by/pdf/3-samson.pdf
https://triplepharm.by/pdf/4-tapalskij.pdf
https://triplepharm.by/pdf/4-tapalskij.pdf
https://triplepharm.by/politika-pers.pdf
https://triplepharm.by/politika-pers.pdf
https://triplepharm.by/politika-pers.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP-EAES.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/dorenem.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/ertapenem.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-2g.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-5g.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/imicinem.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/klaribakcin.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-1-mln.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-2-mln.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-3-mln-i-4-5-mln.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/licenziya.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/meropenem.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/partners.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/policy.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/tejkoplanin.pdf
https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/vankomicin.pdf
https://triplepharm.by/wp-content/uploads/1-doriprem.pdf
https://triplepharm.by/wp-content/uploads/10-article.pdf
https://triplepharm.by/wp-content/uploads/13-article.pdf
https://triplepharm.by/wp-content/uploads/2-article.pdf
https://triplepharm.by/wp-content/uploads/3-article.pdf
https://triplepharm.by/wp-content/uploads/4-article.pdf
https://triplepharm.by/wp-content/uploads/5-article.pdf
https://triplepharm.by/wp-content/uploads/6-article.pdf
https://triplepharm.by/wp-content/uploads/7-article.pdf
https://triplepharm.by/wp-content/uploads/9-article.pdf
https://triplepharm.by/wp-content/uploads/certificatgmp-eaes2025.pdf
https://triplepharm.by/wp-content/uploads/certificatgmp2025.pdf
https://triplepharm.by/wp-content/uploads/dorenem.pdf
https://triplepharm.by/wp-content/uploads/dorenem_en.pdf
https://triplepharm.by/wp-content/uploads/ertapenem.pdf
https://triplepharm.by/wp-content/uploads/ertapenem_en.pdf
https://triplepharm.by/wp-content/uploads/fosfomicin-2g.pdf
https://triplepharm.by/wp-content/uploads/fosfomicin-5g.pdf
https://triplepharm.by/wp-content/uploads/fosfomicin_en.pdf
https://triplepharm.by/wp-content/uploads/imicinem.pdf
https://triplepharm.by/wp-content/uploads/imicinem_en.pdf
https://triplepharm.by/wp-content/uploads/klaribakcin.pdf
https://triplepharm.by/wp-content/uploads/klaribakcin_en.pdf
https://triplepharm.by/wp-content/uploads/kolistat-1-mln.pdf
https://triplepharm.by/wp-content/uploads/kolistat-2-mln.pdf
https://triplepharm.by/wp-content/uploads/kolistat-2-mln_en.pdf
https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln.pdf
https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln_en.pdf
https://triplepharm.by/wp-content/uploads/licenziya.pdf
https://triplepharm.by/wp-content/uploads/meropenem.pdf
https://triplepharm.by/wp-content/uploads/meropenem_en.pdf
https://triplepharm.by/wp-content/uploads/partners.pdf
https://triplepharm.by/wp-content/uploads/policy.pdf
https://triplepharm.by/wp-content/uploads/reprint_patogen-speczifichnaya-terapiya-1.pdf
https://triplepharm.by/wp-content/uploads/tejkoplanin.pdf
https://triplepharm.by/wp-content/uploads/tejkoplanin_en.pdf
https://triplepharm.by/wp-content/uploads/vankomicin.pdf
https://triplepharm.by/wp-content/uploads/vankomicin_en.pdf
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
http://triplepharm.by/assets/files/anketa_soiskatelya_tnk(2).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc
http://triplepharm.by/123.rtf
| 1 | https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf |
| 2 | https://triplepharm.by/%D0%9B%D0%B8%D1%86%D0%B5%D0%BD%D0%B7%D0%B8%D1%8F.pdf |
| 3 | https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf |
| 4 | https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%91%D0%B5%D0%BB.pdf |
| 5 | https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf |
| 6 | https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf |
| 7 | https://triplepharm.by/%D0%A1%D0%B5%D1%80%D1%82%D0%B8%D1%84%D0%B8%D0%BA%D0%B0%D1%82%20GMP%20%D0%95%D0%90%D0%AD%D0%A1.pdf |
| 8 | https://triplepharm.by/assets/files/0305instr/dorenem.pdf |
| 9 | https://triplepharm.by/assets/files/0305instr/dorenem.pdf |
| 10 | https://triplepharm.by/assets/files/0305instr/dorenem.pdf |
| 11 | https://triplepharm.by/assets/files/0305instr/imicinem.pdf |
| 12 | https://triplepharm.by/assets/files/0305instr/imicinem.pdf |
| 13 | https://triplepharm.by/assets/files/0305instr/imicinem.pdf |
| 14 | https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf |
| 15 | https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf |
| 16 | https://triplepharm.by/assets/files/0305instr/klaribakcin.pdf |
| 17 | https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf |
| 18 | https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf |
| 19 | https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-dlya-ingalyacij.pdf |
| 20 | https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf |
| 21 | https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf |
| 22 | https://triplepharm.by/assets/files/0305instr/kolistat-1-mln-me-dlya-vv-vvedeniya.pdf |
| 23 | https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf |
| 24 | https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf |
| 25 | https://triplepharm.by/assets/files/0305instr/kolistat-2-mln-me-dlya-vv-vvedeniya-i-ingalyacij.pdf |
| 26 | https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf |
| 27 | https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf |
| 28 | https://triplepharm.by/assets/files/0305instr/kolistat-2-mln.pdf |
| 29 | https://triplepharm.by/assets/files/0305instr/meropenem.pdf |
| 30 | https://triplepharm.by/assets/files/0305instr/meropenem.pdf |
| 31 | https://triplepharm.by/assets/files/0305instr/meropenem.pdf |
| 32 | https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF |
| 33 | https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF |
| 34 | https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF |
| 35 | https://triplepharm.by/assets/files/0305instr/miomin-instrukciya.PDF |
| 36 | https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf |
| 37 | https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf |
| 38 | https://triplepharm.by/assets/files/0305instr/tejkoplanin.pdf |
| 39 | https://triplepharm.by/assets/files/0305instr/vankomicin.pdf |
| 40 | https://triplepharm.by/assets/files/0305instr/vankomicin.pdf |
| 41 | https://triplepharm.by/assets/files/0305instr/vankomicin.pdf |
| 42 | http://triplepharm.by:80/assets/files/1.pdf |
| 43 | http://triplepharm.by:80/assets/files/1.pdf |
| 44 | http://triplepharm.by:80/assets/files/1.pdf |
| 45 | http://triplepharm.by:80/assets/files/1.pdf |
| 46 | http://www.triplepharm.by:80/assets/files/1.pdf |
| 47 | http://triplepharm.by/assets/files/1.pdf |
| 48 | http://triplepharm.by/assets/files/1.pdf |
| 49 | http://triplepharm.by/assets/files/1.pdf |
| 50 | https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf |
| 51 | https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf |
| 52 | https://triplepharm.by/assets/files/1706/imp-fosfomicin-tf.pdf |
| 53 | https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf |
| 54 | https://triplepharm.by/assets/files/1706/imp_fosfomicin-tf-ing.pdf |
| 55 | https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf |
| 56 | https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf |
| 57 | https://triplepharm.by/assets/files/1706/ohlp-kolistat-3-mln-i-4-5-mln.pdf |
| 58 | http://triplepharm.by:80/assets/files/annot-bronhomoss-utverzh_eng.pdf |
| 59 | http://triplepharm.by:80/assets/files/annot-fitokordium-utverzh_eng.pdf |
| 60 | http://triplepharm.by:80/assets/files/annot-gastroforte-utverzh_eng.pdf |
| 61 | http://triplepharm.by:80/assets/files/annot-sedakalm-utverzh_eng.pdf |
| 62 | http://triplepharm.by:80/assets/files/annot-sinu-fito-utverzh_eng.pdf |
| 63 | http://triplepharm.by:80/assets/files/annot-sinu-kapli-utverzh_eng.pdf |
| 64 | http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf |
| 65 | http://triplepharm.by:80/assets/files/antibiotikorezistentnost.pdf |
| 66 | http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf |
| 67 | http://triplepharm.by/assets/files/antibiotikorezistentnost.pdf |
| 68 | https://triplepharm.by/assets/files/antibiotikorezistentnost.pdf |
| 69 | http://www.triplepharm.by:80/assets/files/Brinamid_eng.pdf |
| 70 | http://triplepharm.by:80/assets/files/bronhomoss-annot.pdf |
| 71 | http://triplepharm.by:80/assets/files/fitokordium-annot.pdf |
| 72 | http://triplepharm.by:80/assets/files/gastroforte-annot.pdf |
| 73 | http://triplepharm.by:80/assets/files/gastroforte-annot.pdf |
| 74 | http://triplepharm.by/assets/files/IMP-Kolistat-avg2016.PDF |
| 75 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/Dorenem-instr.PDF |
| 76 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Klaribakcin.pdf |
| 77 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/IMP-Kolistat-avg2016.PDF |
| 78 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefepim.PDF |
| 79 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-cefosulbaktam.PDF |
| 80 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-imicinem.PDF |
| 81 | http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF |
| 82 | http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF |
| 83 | http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Ivonna-Forte.PDF |
| 84 | http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Ivonna.PDF |
| 85 | http://triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF |
| 86 | http://www.triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF |
| 87 | http://triplepharm.by:80/assets/files/insruktiya-new-rus/Instrukciya-Paulina.PDF |
| 88 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-Tejkoplanin-2017.PDF |
| 89 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/instrukciya-triksocef(14.07.2017).pdf |
| 90 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/Instrukciya-Vankomicin.pdf |
| 91 | https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf |
| 92 | https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf |
| 93 | https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-ingalyacionnyj.pdf |
| 94 | https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf |
| 95 | https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf |
| 96 | https://triplepharm.by/assets/files/insruktiya-new-rus/kolistat-1-vnutrivennyj.pdf |
| 97 | http://www.triplepharm.by/assets/files/insruktiya-new-rus/Meropenem-instr.PDF |
| 98 | http://triplepharm.by/assets/files/instr-kolistat-eng(1).pdf |
| 99 | http://triplepharm.by:80/assets/files/instr-kolistat-eng.pdf |
| 100 | http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf |
| 101 | http://triplepharm.by:80/assets/files/Instr-Tejkoplanin-TF_eng.pdf |
| 102 | http://triplepharm.by/assets/files/Instruction_Benustin_eng.pdf |
| 103 | http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf |
| 104 | http://www.triplepharm.by:80/assets/files/Instruction_Benustin_eng.pdf |
| 105 | http://triplepharm.by/assets/files/Instrukciya-Benustin.PDF |
| 106 | http://www.triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF |
| 107 | http://triplepharm.by:80/assets/files/instrukciya-Brinamid.PDF |
| 108 | http://triplepharm.by:80/assets/files/instrukciya-cefepim-2015.pdf |
| 109 | http://triplepharm.by:80/assets/files/instrukciya-cefepim.PDF |
| 110 | http://triplepharm.by:80/assets/files/instrukciya-cefosulbaktam.pdf |
| 111 | http://triplepharm.by:80/assets/files/instrukciya-dorenem(1).pdf |
| 112 | http://triplepharm.by:80/assets/files/instrukciya-dorenem_eng.pdf |
| 113 | http://triplepharm.by:80/assets/files/instrukciya-imicinem.PDF |
| 114 | http://triplepharm.by:80/assets/files/instrukciya-imipenem-2015.pdf |
| 115 | http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf |
| 116 | http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf |
| 117 | http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf |
| 118 | http://www.triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf |
| 119 | http://triplepharm.by:80/assets/files/Instrukciya-Ivonna_eng(2).pdf |
| 120 | http://triplepharm.by:80/assets/files/instrukciya-kapreocin(1).PDF |
| 121 | https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF |
| 122 | https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF |
| 123 | https://triplepharm.by/assets/files/instrukciya-kapreocin(1).PDF |
| 124 | http://triplepharm.by:80/assets/files/instrukciya-kapreocin-angl.pdf |
| 125 | https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf |
| 126 | http://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf |
| 127 | https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf |
| 128 | https://triplepharm.by/assets/files/instrukciya-kapreocin-angl.pdf |
| 129 | http://www.triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf |
| 130 | https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf |
| 131 | https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf |
| 132 | https://triplepharm.by/assets/files/Instrukciya-Klaribakcin-en.pdf |
| 133 | http://triplepharm.by:80/assets/files/instrukciya-kolistat(1).PDF |
| 134 | http://triplepharm.by:80/assets/files/instrukciya-Meropenem(1).pdf |
| 135 | http://triplepharm.by:80/assets/files/instrukciya-Triksocef_eng.pdf |
| 136 | http://triplepharm.by:80/assets/files/instrukciya-vankomicin(1).pdf |
| 137 | http://triplepharm.by:80/assets/files/instrukciya-vankomicin_eng.pdf |
| 138 | http://triplepharm.by:80/assets/files/InstrukciyaCefosulb-na-utv-----(1).pdf |
| 139 | http://triplepharm.by:80/assets/files/InstrukciyaMeropenem.pdf |
| 140 | http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf |
| 141 | http://triplepharm.by:80/assets/files/InstrukciyaTejkoplanin.pdf |
| 142 | http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf |
| 143 | http://triplepharm.by:80/assets/files/InstrukciyaTriksocef.pdf |
| 144 | http://triplepharm.by:80/assets/files/lechenie-sinegnojnoj-infekcii.pdf |
| 145 | https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf |
| 146 | https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf |
| 147 | https://triplepharm.by/assets/files/new-eng/dorenem-500-mg-dlya-infuzij.pdf |
| 148 | https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf |
| 149 | https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf |
| 150 | https://triplepharm.by/assets/files/new-eng/imicinem-tf-500mg-500-mg-dlya-infuzij.pdf |
| 151 | https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf |
| 152 | https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf |
| 153 | https://triplepharm.by/assets/files/new-eng/meropenem-500-mg-1000-mg-dlya-vv-vvedeniya.pdf |
| 154 | https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf |
| 155 | https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf |
| 156 | https://triplepharm.by/assets/files/new-eng/tejkoplanin-200-400-dlya-vv-i-vm-vvedeniya.pdf |
| 157 | https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf |
| 158 | https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf |
| 159 | https://triplepharm.by/assets/files/new-eng/vankomicin-500-1000-dlya-infuzij.pdf |
| 160 | https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf |
| 161 | https://triplepharm.by/assets/files/PNPC-DOiGI(pilotnPrimTejkopl).pdf |
| 162 | http://triplepharm.by/assets/files/Saj-InstrukciyaPaulina_eng.pdf |
| 163 | http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf |
| 164 | http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf |
| 165 | http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf |
| 166 | http://www.triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf |
| 167 | http://triplepharm.by:80/assets/files/Saj-InstrukciyaPaulina_eng.pdf |
| 168 | http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf |
| 169 | http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf |
| 170 | http://www.triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf |
| 171 | http://triplepharm.by:80/assets/files/Saj-paulina(inst)rus.pdf |
| 172 | http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf |
| 173 | http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf |
| 174 | http://www.triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf |
| 175 | http://triplepharm.by:80/assets/files/SAJT-ivonna(instr)rus.pdf |
| 176 | http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf |
| 177 | http://www.triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf |
| 178 | http://triplepharm.by:80/assets/files/sajt-ivonnaForte(inst)rus.pdf |
| 179 | http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf |
| 180 | http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf |
| 181 | http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf |
| 182 | http://www.triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf |
| 183 | http://triplepharm.by:80/assets/files/SajtIvonnaForte(instr)angl.pdf |
| 184 | http://triplepharm.by:80/assets/files/sedakalm-annot.pdf |
| 185 | http://triplepharm.by:80/assets/files/sinu-fito-annot.pdf |
| 186 | http://triplepharm.by:80/assets/files/sinu-kapli-annot.pdf |
| 187 | http://www.triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf |
| 188 | http://triplepharm.by:80/assets/files/Slavena-forte-instrukciya.pdf |
| 189 | http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf |
| 190 | http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf |
| 191 | http://www.triplepharm.by:80/assets/files/Slavena-instrukciya.pdf |
| 192 | http://triplepharm.by:80/assets/files/Slavena-instrukciya.pdf |
| 193 | https://triplepharm.by/assets/files/tejkoplanin--tf-3.pdf |
| 194 | https://triplepharm.by/att1.pdf |
| 195 | https://triplepharm.by/att1.pdf |
| 196 | https://triplepharm.by/att1.pdf |
| 197 | https://triplepharm.by/licenziya.pdf |
| 198 | https://triplepharm.by/licenziya.pdf |
| 199 | https://triplepharm.by/licenziya.pdf |
| 200 | https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf |
| 201 | https://triplepharm.by/pdf/%D0%94%D0%BE%D0%B7%D0%B8%D1%80%D0%BE%D0%B2%D0%BE%D1%87%D0%BD%D0%B0%D1%8F%20%D0%BC%D0%B0%D1%88%D0%B8%D0%BD%D0%B0%20SP%20100.pdf |
| 202 | https://triplepharm.by/pdf/%D0%9F%D0%BE%D0%BB%D1%83%D0%B0%D0%B2%D1%82%D0%BE%D0%BC%D0%B0%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F%20%D0%BE%D0%B1%D0%BA%D0%B0%D1%82%D0%BA%D0%B0.pdf |
| 203 | https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf |
| 204 | https://triplepharm.by/pdf/%D0%A0%D0%BE%D1%82%D0%BE%D1%80%D0%BD%D1%8B%D0%B9%20%D1%81%D1%82%D0%BE%D0%BB.pdf |
| 205 | https://triplepharm.by/pdf/3-samson.pdf |
| 206 | https://triplepharm.by/pdf/4-tapalskij.pdf |
| 207 | https://triplepharm.by/pdf/4-tapalskij.pdf |
| 208 | https://triplepharm.by/politika-pers.pdf |
| 209 | https://triplepharm.by/politika-pers.pdf |
| 210 | https://triplepharm.by/politika-pers.pdf |
| 211 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP-EAES.pdf |
| 212 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/certificatGMP.pdf |
| 213 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/dorenem.pdf |
| 214 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/ertapenem.pdf |
| 215 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-2g.pdf |
| 216 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/fosfomicin-5g.pdf |
| 217 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/imicinem.pdf |
| 218 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/klaribakcin.pdf |
| 219 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-1-mln.pdf |
| 220 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-2-mln.pdf |
| 221 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/kolistat-3-mln-i-4-5-mln.pdf |
| 222 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/licenziya.pdf |
| 223 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/meropenem.pdf |
| 224 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/partners.pdf |
| 225 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/policy.pdf |
| 226 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/tejkoplanin.pdf |
| 227 | https://triplepharm.by/wp-content/themes/TriplePharm/assets/pdf/vankomicin.pdf |
| 228 | https://triplepharm.by/wp-content/uploads/1-doriprem.pdf |
| 229 | https://triplepharm.by/wp-content/uploads/10-article.pdf |
| 230 | https://triplepharm.by/wp-content/uploads/13-article.pdf |
| 231 | https://triplepharm.by/wp-content/uploads/2-article.pdf |
| 232 | https://triplepharm.by/wp-content/uploads/3-article.pdf |
| 233 | https://triplepharm.by/wp-content/uploads/4-article.pdf |
| 234 | https://triplepharm.by/wp-content/uploads/5-article.pdf |
| 235 | https://triplepharm.by/wp-content/uploads/6-article.pdf |
| 236 | https://triplepharm.by/wp-content/uploads/7-article.pdf |
| 237 | https://triplepharm.by/wp-content/uploads/9-article.pdf |
| 238 | https://triplepharm.by/wp-content/uploads/certificatgmp-eaes2025.pdf |
| 239 | https://triplepharm.by/wp-content/uploads/certificatgmp2025.pdf |
| 240 | https://triplepharm.by/wp-content/uploads/dorenem.pdf |
| 241 | https://triplepharm.by/wp-content/uploads/dorenem_en.pdf |
| 242 | https://triplepharm.by/wp-content/uploads/ertapenem.pdf |
| 243 | https://triplepharm.by/wp-content/uploads/ertapenem_en.pdf |
| 244 | https://triplepharm.by/wp-content/uploads/fosfomicin-2g.pdf |
| 245 | https://triplepharm.by/wp-content/uploads/fosfomicin-5g.pdf |
| 246 | https://triplepharm.by/wp-content/uploads/fosfomicin_en.pdf |
| 247 | https://triplepharm.by/wp-content/uploads/imicinem.pdf |
| 248 | https://triplepharm.by/wp-content/uploads/imicinem_en.pdf |
| 249 | https://triplepharm.by/wp-content/uploads/klaribakcin.pdf |
| 250 | https://triplepharm.by/wp-content/uploads/klaribakcin_en.pdf |
| 251 | https://triplepharm.by/wp-content/uploads/kolistat-1-mln.pdf |
| 252 | https://triplepharm.by/wp-content/uploads/kolistat-2-mln.pdf |
| 253 | https://triplepharm.by/wp-content/uploads/kolistat-2-mln_en.pdf |
| 254 | https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln.pdf |
| 255 | https://triplepharm.by/wp-content/uploads/kolistat-3-mln-i-4-5-mln_en.pdf |
| 256 | https://triplepharm.by/wp-content/uploads/licenziya.pdf |
| 257 | https://triplepharm.by/wp-content/uploads/meropenem.pdf |
| 258 | https://triplepharm.by/wp-content/uploads/meropenem_en.pdf |
| 259 | https://triplepharm.by/wp-content/uploads/partners.pdf |
| 260 | https://triplepharm.by/wp-content/uploads/policy.pdf |
| 261 | https://triplepharm.by/wp-content/uploads/reprint_patogen-speczifichnaya-terapiya-1.pdf |
| 262 | https://triplepharm.by/wp-content/uploads/tejkoplanin.pdf |
| 263 | https://triplepharm.by/wp-content/uploads/tejkoplanin_en.pdf |
| 264 | https://triplepharm.by/wp-content/uploads/vankomicin.pdf |
| 265 | https://triplepharm.by/wp-content/uploads/vankomicin_en.pdf |
| 266 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc |
| 267 | http://triplepharm.by/assets/files/anketa_soiskatelya_tnk(2).doc |
| 268 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc |
| 269 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc |
| 270 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc |
| 271 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc |
| 272 | http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc |
| 273 | http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(2).doc |
| 274 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 275 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 276 | http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 277 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 278 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 279 | http://triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 280 | http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 281 | http://www.triplepharm.by:80/assets/files/anketa_soiskatelya_tnk(4).doc |
| 282 | http://triplepharm.by/123.rtf |